Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
979
datasets available to search
ShareScore release 0.9.0
Dataset results
979 results for “HR”
Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.
ClinicalTrials.gov study NCT06133088. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Bone Quality by vQCT and HR-pQCT:Translation to Multi-center Clinical Research
ClinicalTrials.gov study NCT01544660. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Alinity m HR HPV Specimen Collection Study From Women Undergoing Routine Cervical Cancer Screening
ClinicalTrials.gov study NCT04746872. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients
ClinicalTrials.gov study NCT06009627. IPD Sharing: NO. Countries: 1. Publications: 0.
Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBC
ClinicalTrials.gov study NCT05505175. IPD Sharing: NO. Countries: 1. Publications: 0.
Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer
ClinicalTrials.gov study NCT03706573. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Analysis of Bone Microarchitecture With HR-pQCT of Patients With Chronic Kidney Disease (CKD) Candidates for Renal Transplantation
ClinicalTrials.gov study NCT02523209. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of Predictors of Clinical Outcomes in Patients With HR+ and HER2-low/Negative Breast Cancer
ClinicalTrials.gov study NCT06040593. IPD Sharing: NO. Countries: 1. Publications: 0.
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer
ClinicalTrials.gov study NCT06149130. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer
ClinicalTrials.gov study NCT07037199. IPD Sharing: NO. Countries: 1. Publications: 0.
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC
ClinicalTrials.gov study NCT03439735. IPD Sharing: NO. Countries: 1. Publications: 0.
BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
ClinicalTrials.gov study NCT05977036. IPD Sharing: NO. Countries: 1. Publications: 0.
Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC
ClinicalTrials.gov study NCT04565054. IPD Sharing: NO. Countries: 3. Publications: 0.
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
ClinicalTrials.gov study NCT05693766. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer
ClinicalTrials.gov study NCT07310420. IPD Sharing: NO. Countries: 0. Publications: 0.
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior
ClinicalTrials.gov study NCT07062965. IPD Sharing: YES. Countries: 21. Publications: 0.
The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis
ClinicalTrials.gov study NCT05431504. IPD Sharing: NO. Countries: 1. Publications: 0.
High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant
ClinicalTrials.gov study NCT01941680. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer
ClinicalTrials.gov study NCT02769104. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor
ClinicalTrials.gov study NCT06996093. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.